Alternative and New Radiopharmaceutical Agents for Lung Cancer

Silvi Telo1,*, Letizia Calderoni1, Sara Vichi2, Federico Zagni3, Paolo Castellucci1 and Stefano Fanti1

1Department of Metropolitan Nuclear Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 2Nuclear Engineering Laboratory of Montecuccolino, University of Bologna, Bologna, Italy; 3Medical Physics Department, Sant’Orsola-Malpighi hospital, University of Bologna, Bologna, Italy

Abstract: Background: FDG PET/CT imaging has an established role in lung cancer (LC) management. Whilst it is a sensitive technique, FDG PET/CT has a limited specificity in the differentiation between LC and benign conditions and is not capable of defining LC heterogeneity since FDG uptake varies between histotypes.

Objective: To get an overview of new radiopharmaceuticals for the study of cancer biology features beyond glucose metabolism in LC.

Methods: A comprehensive literature review of PubMed/Medline was performed using a combination of the following keywords: “positron emission tomography”, “lung neoplasms”, “non-FDG”, “radiopharmaceuticals”, “tracers”.

Results: Evidences suggest that proliferation markers, such as 18F-Fluorothymidine and 11C-Methionine, improve LC staging and are useful in evaluating treatment response and progression free survival. 68Ga-DOTA-peptides are already routinely used in pulmonary neuroendocrine neoplasms (NENs) management and should be firstly performed in suspected NENs. 18F-Fluoromisonidazole and other radiopharmaceuticals show a promising impact on staging, prognosis assessment and therapy response in LC patients, by visualizing hypoxia and perfusion. Radiolabeled RGD-peptides, targeting angiogenesis, may have a role in LC staging, treatment outcome and therapy. PET radiopharmaceuticals tracing a specific oncogene/signal pathway, such as EGFR or ALK, are gaining interest especially for therapeutic implications. Other PET tracers, like 68Ga-PSMA-peptides or radiolabeled FAPIs, need more development in LC, though, they are promising for therapy purposes.

Conclusion: To date, the employment of most of the described tracers is limited to the experimental field, however, research development may offer innovative opportunities to improve LC staging, characterization, stratification and response assessment in an era of increased personalized therapy.

Keywords: Lung cancer, PET/CT, radiopharmaceuticals, non-FDG tracers, tomoscintigraphy, alternative tracers, new radiopharmaceuticals.

1. INTRODUCTION

Lung cancer (LC) is the leading cause of cancer-related death worldwide, accounting for nearly 17% of all cancer-related deaths [1]. LC is histologically classified into small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC), pulmonary neuroendocrine neoplasms (NENs), and others [2]. Among NSCLC, which is the most common type [3], squamous cell carcinoma (SCC), adenocarcinoma and large-cell carcinoma are included [4].

Positron emission tomography/computed-tomography (PET/CT), as well as conventional chest radiography and computed tomography (CT), plays an important role in staging, restaging, evaluation of treatment response and prognosis assessment in LC [5]. 18F-Fluorodeoxyglucose (FDG) is nowadays the most commonly used radiotracer for pulmonary malignancies evaluation. FDG is internalized in the cell by glucose transporters (GLUT-1 and GLUT-3) and phosphorylated by a hexokinase but does not undergo further metabolism in the glucose pathway. FDG is therefore trapped within cells [6]. This uptake is nonspecific for malignancies, which is indeed observed in various conditions, such as infective/inflammatory processes (e.g. pneumonias, abscesses and aspergillosis or granulomatous conditions like sarcoidosis or tuberculosis). Therefore, FDG PET/CT has a high false-positive rate in the staging of pulmonary nodules, especially in those geographic areas with a high prevalence of infectious lung diseases [7]. Furthermore, FDG uptake is
variable among different LC histotypes: adenocarcinomas are generally less FDG-avid than SCC, while pulmonary NEs, mucinous neoplasms and lepidic predominant adenocarcinomas show low FDG uptake [8, 9]. To investigate other aspects of the pathological lung cancer biology, in addition to glucose metabolism, could be useful in characterizing different tumor histotypes and predicting the response to new targeted therapies against cancer [10]. Recent developments of new radiopharmaceuticals are gaining interest in order to improve the sensitivity and specificity of PET/CT imaging in LC in terms of characterization, treatment stratification and therapeutic monitoring [11]. The main purpose of this article is to review non-FDG PET tracers in LC. A comprehensive literature review of PubMed/Medline was performed using a combination of the following keywords: “positron emission tomography”, “lung neoplasms”, “non-FDG”, “radiopharmaceuticals”, “tracers”. No date limit or language restrictions were applied, and the research included articles published online up through September 2018. A total of 194 records including 18 review articles were identified and the most pertinent articles are discussed herein.

2. PET IMAGING OF CELLULAR PROLIFERATION

2.1. 18F-Fluorothymidine

18F-fluorothymidine (FLT) is a thymidine analog in which the 3′-hydroxy group is replaced by 18F-fluorine. FLT is a marker of cellular proliferation and follows the salvage pathway of thymidine being phosphorylated by thymidine kinase 1 and trapped inside the cell during the S-phase, but not incorporated into DNA [12]. Uncontrolled cell proliferation is a key feature of malignant processes, and FLT uptake in tumor cells correlates with Ki-67 expression in many neoplasms, including NSCLC [13]. Buck et al. [14], Tian et al. [15], Halter et al. [16] and Li et al. [17] compared FLT to FDG PET/CT and found that the first is more specific and equally or more accurate in the detection of primitive LC. Furthermore, according to Yang et al. [18], FLT is more specific than FDG PET/CT in detecting lung cancer lymph node metastasis. Data from about all these studies show, however, that sensitivity and accuracy in detecting primitive LC and pathologic lymph nodes are lower for FLT than for FDG PET/CT. Trigonis et al. [19] found that, across a group of NSCLC patients, radiation therapy induces an early significant lesion FLT uptake decrease, exceeding test-retest variability. Therefore, FLT PET/CT seems to be useful in evaluating treatment response in patients with NSCLC. This was confirmed by Everitt et al. [20] who evaluated proliferation during radical chemotherapy in 20 NSCLC patients with both FDG and FLT PET/CT and found that FLT uptake correlates with treatment response better than FDG uptake.

FLT PET/CT has also a prognostic role in NSCLC patients: Kobe and colleagues [21] found that residual FDG uptake measured at different times has a prognostic role in NSCLC patients treated with Erlotinib. Additionally, lower residual FDG and FLT uptake during therapy with Erlotinib is associated with improved progression-free survival.

2.2. 11C-Methionine

Tumor proliferation leads to an up-regulated protein metabolism. 11C-Methionine (MET) directly reflects amino acid transport, being methionine an essential amino acid and an intermediate in phospholipid biosynthesis. MET doesn’t have physiological uptake in the brain, for this reason, it has been used mostly for detecting brain tumors and could be a suitable tracer for investigating brain metastases [22, 23]. MET has a role in differentiating benign and malignant thoracic nodules. Hsieh et al. [24] and Sasaki et al. [25] found that sensitivity, specificity and accuracy in detecting lung malignancies are higher with MET PET/CT than with FDG PET/CT. Instead Kanegae and colleagues [26], comparing the two radiopharmaceuticals and analyzing their capability of differentiation between LC and benign conditions, concluded that sensitivity is higher for MET PET/CT and accuracy is the same.

2.3. 11C-Choline and 18F-Fluorocholine

Choline, as a quaternary ammonium base, is a precursor of cell membrane phospholipids. Cellular membrane construction requires choline transport and acetylcholine production. Choline is phosphorylated and is further incorporated into phosphatidylcholine and metabolized through acetylation [27]. Increased choline metabolism is typical of oncogenesis and tumor growth processes [28]. 11C-Choline (Fig. 1) and 18F-Fluorocholine are radiopharmaceuticals used...
to identify neoplastic tissue since an increase in cell proliferation is associated with an increase in choline cellular component. Apart from prostate adenocarcinoma imaging, where it is mostly employed, $^{11}\text{C}$-Choline is known to have good performances in other malignancies, such as hepatocellular carcinoma, glioma, bone tumor, soft-tissue tumors, and lung cancer [29]. Furthermore, $^{11}\text{C}$-Choline PET/CT has several advantages over FDG PET/CT: first, fasting is not required before examination, radiation exposure from $^{11}\text{C}$-Choline is less than that from $^{18}\text{F}$-FDG because the half-life is much shorter, and less time is required for the examination (in Table 1 physical features of the different isotopes). By contrast, $^{11}\text{C}$-Choline is not a specific tracer for cancer cells as well as FDG. Granulation processes cells need plenty of choline for cell membrane synthesis. Highly differentiated and low malignant degree neoplasms, such as alveolar cancer, have a low choline metabolism and usually appear as false negatives at $^{11}\text{C}$-Choline PET/CT [30, 31]. In addition, some authors demonstrate the advantage of FDG PET/CT over $^{11}\text{C}$-Choline PET/CT in the diagnosis of metastatic lymph nodes [32]. On the contrary, according to Hara et al. [33], $^{11}\text{C}$-Choline PET/CT may be superior to FDG PET/CT in the diagnosis of lymph node metastasis. Especially for granulomatous lymph nodes, uptake of choline is increased, due to the exuberant macrophages metabolism.

3. PET IMAGING IN PULMONARY NENS

3.1. $^{68}\text{Ga}$-DOTA Peptides

NENs are a heterogeneous group of malignancies that develop from neuroendocrine cells in different organs, such as lungs. One of the classifications of gastro-entero-pancreatic NENs is based on their mitotic count or Ki-67 index, associated with cellular proliferation; while grade refers to the proliferative activity of these malignancies, measured by Ki-67 index or mitotic activity, differentiation refers to the extent of resemblance between tumor cells and their normal counterparts. Well differentiated (grade 1) and moderately differentiated (grade 2) NENs express, respectively a high and moderated density of surface somatostatin receptors (SSTRs), while low differentiated NENs (grade 3) express low densities of SSTRs. Classification of pulmonary NENs, representing 1%-2% of all lung malignancies, include typical carcinoids, well differentiated and with a better prognosis, and atypical carcinoids, low differentiated and with a worst prognosis. The binding mechanism between somatostatin analogs and SSTRs is the base for the theranostic approach that characterizes NENs. In high density SSTRs-NENs $^{68}\text{Ga}$-DOTA peptides, (obtained from labeling a synthetic and stable somatostatin analog with a $\beta$-emitting radionuclide) bind the SSTRs allowing imaging. Therapy can be performed using a synthetic and stable somatostatin analog linked to a higher $\beta$-emitting radioisotope allowing peptide radionuclide receptor therapy (PRRT) [34, 35].

Up to 10% of NSCLC show neuroendocrine differentiation. Compared to FDG, $^{68}\text{Ga}$-DOTA-peptides (Fig. 2) are easy to label and synthesize and offer the possibility to image somatostatin receptor expression with direct therapeutic implications [36]. Venkitaraman et al. [37] found that $^{68}\text{Ga}$-DOTA-TOC PET/CT shows better specificity, sensitivity and accuracy than FDG PET/CT in patients with the suspect of pulmonary NENs. Walker et al. [38] confirmed that specificity is higher in $^{68}\text{Ga}$-DOTA PET/CT than in FDG PET/CT in the evaluation of indeterminate pulmonary nodules. Li et al. [39] found that in a group of NSCLC patients $^{68}\text{Ga}$-DOTA-TATE is more specific than FDG and accuracy between the two radiopharmaceuticals does not show significant differences.

$^{68}\text{Ga}$-somatostatin analogs should be the first choice in the initial evaluation of patients with suspected pulmonary NENs and, in case of negative result, FDG PET/CT could be performed [40]. However, FDG PET/CT is more sensitive for undifferentiated pulmonary NENs. In some cases, performing a dual tracer PET/CT can provide useful information in the management of patients with pulmonary NENs [41].

4. PET IMAGING OF HYPOXIA

4.1. $^{18}\text{F}$-Fluoromisonidazole

In malignancies, including NSCLC, hypoxia is associated with resistance to treatment and a poor outcome [42]. $^{18}\text{F}$-Fluoromisonidazole (FMISO), the most studied hypoxia tracer, enters the cell with low oxygen level by passive diffusion and is trapped after a reduction reaction [43]. Gagel et al. [44] found that FMISO PET/CT provides qualitative and quantitative information about hypoxic areas, which may correspond to local recurrences, in NSCLC patients. Furthermore, changes in FMISO PET/CT, in addition to FDG PET/CT, give information about early response to therapy

| Isotope | $^{11}\text{C}$ | $^{18}\text{F}$ | $^{68}\text{Ga}$ | $^{64}\text{Cu}$ |
|---------|----------------|----------------|----------------|----------------|
| Half-life | 20.4 min | 110 min | 67.8 min | 12.7 h |
| Branching ($\beta^+$) in % | 99.8 | 96.9 | 89.1 | 17.5 |
| E max (MeV) | 0.96 | 0.634 | 1.899 | 0.653 |
| E mean (MeV) | 0.386 | 0.25 | 0.89 | 0.278 |
| Range mean (mm) | 1.2 | 0.6 | 2.9 | 0.7 |
| Pure/non-pure | pure | pure | $\gamma$ 1.077 MeV | $\beta$- 34% |
| Production method | Cyclotron (gas target) | Cyclotron (liquid target) | $^{68}\text{Ge}$/$^{68}\text{Ga}$ Generator | Cyclotron (solid target) |
A

Fig. (2). MIP (A) and axial PET/CT scan (B) of a patient with Typical Pulmonary NEN (Ki67=4%) undergoing 68Ga-DOTANOC PET/CT for staging. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

B

and may predict progression free disease, as well as overall survival. Vera et al. [45] investigated NSCLC patients with PET/CT using three tracers: FLT, FDG and FMISO performed simultaneously before and during radiotherapy (RT). A significant correlation was observed between FLT and FDG uptake before and during RT, while FDG and FMISO uptake were significantly correlated during RT. A fast decrease in tumor proliferation exists during RT with differences in metabolism and hypoxia. Arvold et al. [46] found that FMISO PET/CT detects variations in tumor hypoxia after hypoxia target therapy (with EGFR-tyrosine kinase inhibitors) in EGFR-mutant NSCLC both preclinically and clinically. Whether FMISO PET/CT could be used in imaging for the early evaluation of treatment response after hypoxia-reducing therapies in EGFR-mutant NSCLC remains to be tested in a larger cohort [46].

4.2. 64Cu-Dyacetil-Bis(N4-Methylthiosemicarbazone)

64Cu-Diacetyl-Bis(N4-methylthiosemicarbazone) (Cu-ATSM) is a promising PET radiopharmaceutical for tumor imaging of hypoxia. Copper has several positron-emitting radioisotopes, including 64Cu, which is the most commonly used for its long half-life that allows distant distribution. There are clinical evidences that Cu-ATSM PET/CT is feasible in NSCLC and may play a role as a prognostic marker. One of the advantages of this compound, compared with other hypoxia-avid tracers, is the high tumor-to-background signal offered, which guarantees facilitated tumor delineation [47]. Lopci et al. [48] evaluated optimal semi-quantitative and quantitative parameters obtained by Cu-ATSM PET/CT in patients with locally advanced NSCLC and neck cancer and observed that hypoxic tumor volume and hypoxic burden (=hypoxic tumor volume x mean SUV) has a significant correlation to progression free survival. In the study performed by Zhang et al. [49] Cu-ATSM PET/CT scans show that evaluating lung neoplasms by visualizing hypoxia and perfusion is a promising technique.

4.3. 18F-Fluoroazomycin Arabinoside

18F-Fluoroazomycin arabinoside (FAZA) is a nitroimidazole compound which is reduced and trapped within the cell under hypoxic conditions. Compared to FMISO, FAZA shows superior biokinetics and is, thus, a promising PET tracer for the visualization of tumor hypoxia [50]. Di Perri et al. [51] studied patients with non resecable LC with FDG and FAZA PET/CT prior and during RT and the radiopharmaceuticals uptake distributions displayed unexpectedly strong similarity. Saga et al. [52] demonstrated that in patients with advanced NSCLC, FAZA uptake in lymph nodes is predictive of treatment outcome.

5. PET IMAGING OF ANGIOGENESIS

5.1. Radiolabeled Integrin Antagonists

Angiogenesis leads to the creation of new blood vessels and is involved in various pathological processes, including solid tumor growth and metastasis. Integrins are cell adhesion molecules upregulated on activated endothelial cells in association with tumor angiogenesis [53]. Integrin αvβ3 represents the most studied protein of the integrins group. The arginine-glycine-aspartic acid (RGD) sequence on ligands allows bindings between integrin αvβ3 and extra cellular matrix molecules [54]. PET imaging with radiolabeled RGD-peptides, because of their high affinity and selectivity for integrin αvβ3, is a useful tool for the study of angiogenesis. It has been shown that RGD-peptides labeled with 18F have a good tumor specificity and are eliminated through urine in a short period [55]. Beer et al. [56] investigated 18F-Galacto-RGD and revealed no significant correlation between FDG SUVs and 18F-galacto-RGD SUVs in NSCLC patients with primary or metastatic lesions. Zheng and colleagues [57] investigated 68Ga-labelled RGD tracers in LC and found that 68Ga-NOTA-PRGD2 PET/CT has a similar diagnostic value for lung malignancies compared to FDG PET/CT and has higher specificity in the diagnosis of lymph node metastasis. A recent effort to label RGD peptides had lead to the development of 18F-AIF-NOTA-PRGD2 (18F-alfatide) which is produced with higher purity and with a simpler process than 18F-labeled RGD peptides. 18F-alfatide was used as a PET tracer by Luan et al. in patients with advanced NSCLC before therapy. They concluded that SUVmax, peakSUV and tumor to tissue ratios are higher in non-responders compared to responders [58].
5.2. VEGF Pathway

5.2.1. $^{64}$Cu-NOTA-RamAb

The vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein that binds to a VEGF tyrosine kinase receptor and initiates a signaling cascade that mediates endothelial cell migration and proliferation. VEGF pathway inhibitors showed improvements in response, progression free survival and overall survival in NSCLC patients and in patients with other neoplasms [59]. This pathway represents an interesting PET imaging target for angiogenesis [60]. A recent study made by Luo et al. gives initial evidence that $^{64}$Cu-NOTA-RamAb can be useful as a PET tracer for imaging of VEGFR-2 expression in vivo, which may also find potential applications in monitoring the treatment response of VEGFR-2-targeted cancer therapy [61].

6. PET TRACERS FOR TARGETED THERAPIES

6.1. Immune Related Radiopharmaceuticals

6.1.1. PDL-1 Checkpoint

Immunotherapy with checkpoint inhibitors, such as anti-PDL-1 drugs, represents a new effective treatment option for many tumor types, such as NSCLC. Conventional criteria to access response can fail in the correct evaluation of immune-related responses. Some patients may show pseudo-progression due to the apparent rise of tumor burden connected to inflammatory cells infiltrating the tumor, and this can lead to early or unnecessary interruption of immunotherapy. The activation of the immune system in responders might determine an early increase of FDG uptake in these patients. FDG is not specific as required in the evaluation of response during immunotherapy. For this reason, immuno-PET/CT can be useful to access response and to select patients who will undergo immunotherapy [62]. This technique is based on monoclonal antibodies combined with radioactive elements. Most of these radiopharmaceuticals have been tested in preclinical studies and require clinical validation [63-65].

6.2. Radiopharmaceuticals for Targeted Molecular Therapy

6.2.1. EGFR Pathway

Targeted biological therapy and molecular characterization are features of modern medicine. Molecular diagnostics are now a fundamental part in the clinical management of various malignancies including NSCLC; LC is categorized by histological subtypes and, in addition, by testing for EGFR mutation, recommended by the 2017 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology [66].

6.2.1.1. $^{11}$C- Erlotinib

The epidermal growth factor receptor (EGFR) is involved in the pathogenesis and progression of different types of carcinoma [67]. In patients with activated EGFR mutation target therapy with tyrosine-kinase inhibitors (TKIs) such as Erlotinib can be considered. Erlotinib inhibits signaling through the EGFR pathway and this kind of treatment reached a great success [68, 69]. $^{11}$C-Erlotinib is a novel PET tracer targeting the EGFR-TKI signaling pathway. Memon et al. showed evidence that this tracer accumulates in NSCLC and in lymph nodes not detected by FDG PET/CT in humans. Furthermore, $^{11}$C-Erlotinib may be useful for the selection of patients suitable for Erlotinib treatment [70]. In literature, there are conflicting results about the correlation between FDG uptake and EGFR mutations [71-73].

6.2.1.2. $^{11}$C-PD153035

Another promising imaging biomarker of EGFR pathway is $^{11}$C-PD153035. It has been shown that this tracer predicts outcomes in chemotherapy refractory patients with advanced NSCLC treated with EGFR-TKIs and may be used to select this kind of patients. Meng et al. studied 21 patients with advanced NSCLC nonresponsive to chemotherapy and radiotherapy during and after Erlotinib treatment and concluded that higher baseline SUVmax correlates with longer overall survival and progression free survival. Despite these findings, this tracer was not good for monitoring treatment response [74].

6.2.2. ALK Pathway and $^{18}$F-Fluoroethyl-Ceritinib

Anaplastic lymphoma kinase (ALK) is an oncogenic receptor tyrosine kinase which belongs to the insulin receptor superfamily. Mutated ALK proteins are involved in the development of various malignant processes like hematologic malignancies and NSCLC [75]. ALK is a therapeutic target in these malignancies. Some of the ALK mutations are linked to better response to ALK-inhibitors like Crizotinib, Ceritinib and Alectinib, whereas, some other mutations are connected to resistance to therapy [76, 77]. Perera et al. have synthetized a new tracer called $^{18}$F-fluoroethyl-ceritinib for the study of solid malignancies that overexpress ALK although further in vitro and in vivo studies are needed to test this potential PET imaging agent. The current lack of diagnostic assays and markers predictive of disease sensitivity to ALK inhibition in vivo may limit the ability to properly select patients for clinical trials of drugs targeting the ALK kinase. ALK-specific-radiolabeled-agents-PET could provide enhanced assessment of the relative levels and heterogeneity of ALK protein in tumors and thus hone the selection criteria for the inclusion of patients in redesigned clinical trials [78, 79].

6.3. Radiopharmaceuticals for Theranostic Applications

6.3.1. $^{68}$Ga-PSMA Peptides

PSMA is a type II transmembrane protein with glutamate carboxypeptidase/folate hydrolase activity [80]. Human PSMA is composed of a big extracellular domain, a transmembrane part and an intracellular segment. Binding of the PSMA ligand to its anchored-cell membrane target mediates internalization [81]. This leads to enhanced retention of conjugated radionuclides into the cells even in small volume sites of disease, which enables high quality image acquisition for diagnostic procedures and high local dose for therapeutic applications [82]. $^{68}$Ga -PSMA-11 ($^{68}$Ga-PSMA-Glu-urea-Lys-(Ahx)-BED-CC) (GaPSMA) was introduced by the German Cancer Research Centre (Heidelberg, Germany) in May 2011 [83-85]. Since then GaPSMA has been widely
used for prostate cancer imaging. Biodistribution studies on dynamic GaPSMA PET imaging demonstrated sufficiently high radiotracer uptake in tumor lesions as early as five minutes post injection. Lesion-to-background ratios and SUVmax values of primary tumors, lymph nodes and bone malignancies significantly increase over time, mediated by GaPSMA internalization [86, 87]. GaPSMA uptake is high not only in prostate cancer lesions, but also in several other benign and malignant conditions (Fig. 3). Schmidt et al. analyzed 275 samples of NSCLC tissue specimens and reported that PSMA tumor cell expression in NSCLC was about 6% and was predominantly found in squamous cell carcinoma, while neovascular PSMA expression was found in 49% of NSCLC [88].

Some case reports demonstrated the incidental detection of synchronous primary and metastatic lesions from other malignancies such as LC on imaging being performed for prostate cancer management. However, it is not possible to discriminate prostate cancer lung metastases from primary lung cancers and from inflammatory conditions, neither from a qualitative nor from a semi-quantitative point of view [89, 90].

![Fig. (3)](image)

Fig. (3). Coronal (A) and axial (B) scans of a biochemical recurrent prostate cancer patient undergoing $^{68}$Ga-PSMA-11 PET/CT with a finding consistent with NSCLC. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

Jochumsen et al. reported a case of a man recently diagnosed with prostate cancer who underwent GaPSMA PET/CT which revealed an intense uptake in a lung nodule characterized by no significant uptake to FDG [91].

PSMA overexpression in other malignancies could pave the way potentially to expand the already promising therapeutic application of PSMA-targeted radioligands [92].

### 6.3.2. Radiolabeled FAPIs

Loktev et al. developed a DOTA-coupled radiotracer based on a fibroblast activation protein inhibitor (FAPI). Cancer-associated fibroblasts overexpressing FAP and extracellular fibrosis can contribute up to 90% of the gross tumor mass. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities including LC. Biodistribution studies on the first patients demonstrated high uptake of the tracer in malignant tissues and fast body clearance, resulting in promising images and exposure of healthy tissue to radiation similar to other routinely used radiopharmaceuticals.

A comparison with 18F-FDG in a patient with locally advanced lung adenocarcinoma revealed that FAP ligand was clearly superior. Furthermore, coupling of these molecules to DOTA or other chelators, allows labeling not only with $^{68}$Ga but also with therapeutic isotopes [93].

### CONCLUSION

FDG PET/CT imaging has an established role in staging, restaging, treatment planning and prognosis assessment in LC. Pitfalls may be encountered in cases of infectious/inflammatory diseases, due to the high glucose uptake of inflammatory cells, in the visualization of brain metastasis for the physiologic FDG uptake in brain tissue and in some low FDG-avid LC histotypes, such as NENs, mucinous neoplasms and lepidic predominant adenocarcinoma. New and alternative radiopharmaceutical agents, targeting different aspects of tumor biology, such as proliferation, hypoxia, angiogenesis and a specific onco-necisignal pathway, are gaining interest. On the other hand, some non-FDG tracers (DOTA peptides) are already routinely used in pulmonary NENs management. Concerning the other radiopharmaceuticals described in this review, more development is still needed. Further research and clinical studies are mandatory to improve non-invasive LC management.

### LIST OF ABBREVIATIONS

- $^{11}$C = Carbon-11
- $^{11}$C-PD153035 = $^{11}$C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline
- $^{64}$Cu = Curium-64
- DOTATATE = (DOTA$^{0}$-Tyr$^{3}$) octreotate
- DOTATOC = (DOTA$^{0}$-Tyr$^{3}$) octreotide
- $^{18}$F = Fluorodeoxyglucose
- $^{68}$Ga = Gallium-68
- MIP = Maximum Intensity Projection
- SUV = Standardized Uptake Value
CONSENT FOR PUBLICATION
Not applicable.

FUNDING
None.

CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS
Declared none.

REFERENCES
[1] Ferlay, J.; Colombet, M.; Soerjomataram, I.; Dyba, T.; Randi, G.; Bettio, M.; Gavin, A.; Visser, O.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer, 2018, 103, 356-387. http://dx.doi.org/10.1016/j.ejca.2018.07.005 PMID: 30100160
[2] Brennan, P.; Hainaut, P.; Boffetta, P. Genetics of lung-cancer susceptibility. Lancet Oncol., 2011, 12(4), 399-408. http://dx.doi.org/10.1016/S1470-2045(11)70216-1 PMID: 21951091
[3] Jamal-Hanjani, M.; Wilson, G.A.; McGonagle, N.; Birkbak, N.J.; Watkins, T.B.K.; Veeriah, S.; Shafi, S.; Johnson, D.H.; Mitter, R.; Rosenenthal, R.; Salm, M.; Horswill, S.; Escudero, M.; Matthews, N.; Rowan, A.; Chambers, T.; Moore, D.A.; Turajlic, S.; Xu, H.; Lee, S.M.; Forster, M.D.; Ahmad, T.; Hiley, C.T.; Abbosh, C.; Falzon, M.; Baten, M.; MacManus, M.; Middlemas, A.; Nofal, N.; Nalbandian, H.; Kerr, K.; Cheadle, A.; Topham, K.; Jemal, A.; Kratochwil, C.; Wahl, A.; Glatting, G.; Mottaghy, F.M.; Mattfeldt, T.; Neumaier, B.; Reske, S.N. Clinical relevance of imaging proliferative activity in lung nodules. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(5), 525-533. http://dx.doi.org/10.1007/s00259-004-1706-7 PMID: 15599526
[4] Tian, J.; Yang, X.; Yu, L.; Chen, P.; Xin, J.; Ma, L.; Feng, H.; Tan, Y.; Zhao, Z.; Wu, W. A multicenter clinical trial on the diagnostic value of [18F]FDG-PET imaging in the differentiation of brain tumor recurrence from post-radiotherapy edema. PLoS One., 2015, 10(7), e0131631. PMID: 26160211
[5] Tian, J.; Yang, X.; Yu, L.; Chen, P.; Xin, J.; Ma, L.; Feng, H.; Tan, Y.; Zhao, Z.; Wu, W. A multicenter clinical trial on the diagnostic value of [18F]FDG-PET imaging in the differentiation of brain tumor recurrence from post-radiotherapy edema. PLoS One., 2015, 10(7), e0131631. PMID: 26160211
[6] Yang, W.; Zhang, Y.; Fu, Z.; Sun, X.; Mu, D.; Yu, J. Imaging proliferation of 18F-FDG PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(8), 1289-1296. http://dx.doi.org/10.1007/s00259-012-2126-8 PMID: 22581165
[7] Yang, W.; Zhang, Y.; Fu, Z.; Sun, X.; Mu, D.; Yu, J. Imaging proliferation of 18F-FDG PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(8), 1289-1296. http://dx.doi.org/10.1007/s00259-012-2126-8 PMID: 22581165
[8] Trigonis, I.; Koh, P.K.; Taylor, B.; Tamal, M.; Ryder, D.; Earl, M.; Antônio-Rodriguez, J.; Haslett, K.; Young, H.; Faivre-Finn, C.; Blackhall, F.; Jackson, A.; Asselin, M.C.; Hackshaw, A.; Li, X-F.; Dai, D.; Song, X-Y.; Liu, J-J.; Zhu, Y-J.; Xu, W-G. Comparison of the diagnostic performance of [18F]FDG versus [18F]fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis. J. Nucl. Med., 2015, 56(1), 101-108. http://dx.doi.org/10.2967/jnumed.114.140315 PMID: 24777140
[9] Nariai, T.; Tanaka, Y.; Wakimoto, H.; Aoyagi, M.; Tamaki, M.; Ishii, K.; Hirakawa, K.; Ohno, K. Usefulness of [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer treated with erlotinib. Eur. J. Cancer, 2015, 51(13), 2674-2684. http://dx.doi.org/10.1016/j.ejca.2015.01.009 PMID: 25496728
[10] Trigonis, I.; Koh, P.K.; Taylor, B.; Tamal, M.; Ryder, D.; Earl, M.; Antônio-Rodriguez, J.; Haslett, K.; Young, H.; Faivre-Finn, C.; Blackhall, F.; Jackson, A.; Asselin, M.C. Early reduction in tumour ent SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur. J. Cancer, 2015, 51(13), 2674-2684. http://dx.doi.org/10.1016/j.ejca.2015.01.009 PMID: 25496728
[11] Topham, K.; Jemal, A.; Kratochwil, C.; Wahl, A.; Glatting, G.; Mottaghy, F.M.; Mattfeldt, T.; Neumaier, B.; Reske, S.N. Clinical relevance of imaging proliferative activity in lung nodules. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(5), 525-533. http://dx.doi.org/10.1007/s00259-004-1706-7 PMID: 15599526
[12] Cheng, G. Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose. PET Clin., 2018, 13(1), 73-81. http://dx.doi.org/10.1016/j.petc.2017.09.006 PMID: 29157387
[13] Buck, A.K.; Halter, G.; Schirmeister, H.; Kotzerke, J.; Wurziger, I.; Glatting, G.; Mattfeldt, T.; Neumaier, B.; Reske, S.N.; Hetzel, M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med., 2003, 44(9), 1426-1431. PMID: 12960187
[14] Yang, W.; Zhang, Y.; Fu, Z.; Sun, X.; Mu, D.; Yu, J. Imaging proliferation of 18F-FDG PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(8), 1289-1296. http://dx.doi.org/10.1007/s00259-012-2126-8 PMID: 22581165
[15] Halter, G.; Buck, A.K.; Schirmeister, H.; Wurziger, I.; Liewald, F.; Glatting, G.; Neumaier, B.; Sunder-Plassmann, L.; Reske, S.N.; Hetzel, M. [18F] 3-deoxy-3-fluoromethyldone positron emission tomography: alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J. Thorac. Cardiovasc. Surg., 2004, 127(4), 1093-1099. http://dx.doi.org/10.1016/j.jtcvs.2003.09.003 PMID: 15052207
[16] Li, X-F.; Dai, D.; Song, X-Y.; Liu, J-J.; Zhu, Y-J.; Xu, W-G. Comparison of the diagnostic performance of [18F]fluorodeoxyglucose versus [18F]fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta-analysis. J. Nucl. Med., 2015, 56(1), 101-108. http://dx.doi.org/10.2967/jnumed.114.140440 PMID: 25469278
[17] Yang, W.; Zhang, Y.; Fu, Z.; Yu, J.; Sun, X.; Mu, D.; Han, A. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(7), 1291-1299. http://dx.doi.org/10.1007/s00259-010-1412-6 PMID: 20309686
[18] Everitt, S.J.; Ball, D.L.; Hicks, R.J.; Callahan, J.; Plumridge, N.; Li, X-F.; Dai, D.; Song, X-Y.; Liu, J-J.; Zhu, Y-J.; Xu, W-G. Comparison of the diagnostic performance of [18F]FDG versus [18F]fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta-analysis. J. Nucl. Med., 2015, 56(1), 101-108. http://dx.doi.org/10.2967/jnumed.114.140440 PMID: 25469278
[19] Nariai, T.; Tanaka, Y.; Nakahara, K.; Kawahara, H.; Kanno, A.; Katayama, T.; Hidaka, A.; Takada, Y.; Hiyama, K.; Hattori, M.; Matsuoka, K. Differential (18F)-FDG and (18F)-FLT Uptake on Secon-
192 Current Radiopharmaceuticals, 2020, Vol. 13, No. 3

http://dx.doi.org/10.3171/jns.2005.103.3.0498 PMID: 16235683

[24] Hsieh, H.J.; Lin, S.H.; Lin, K.H.; Lee, C.Y.; Chang, C.P.; Wang, S.J. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. *Ann. Nucl. Med.*, 2008, 22(6), 533-538. http://dx.doi.org/10.1007/s12149-007-0142-8 PMID: 18670862

[25] Susuki, M.; Kawabara, Y.; Yoshiida, T.; Nakagawa, M.; Koga, H.; Hayashi, K.; Kaneko, K.; Chen, T.; Ichiya, Y.; Masuda, K. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung. *Ann. Nucl. Med.*, 2001, 15(5), 425-431. http://dx.doi.org/10.1007/BF02988346 PMID: 11758947

[26] Kanegas, K.; Nakano, I.; Kimura, K.; Kaji, H.; Kuge, Y.; Shiga, T.; Zhang, X.; Okamoto, S.; Tamakii, N. PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumonia. *Ann. Nucl. Med.*, 2007, 21(6), 331-337. http://dx.doi.org/10.1007/s12149-007-0035-x PMID: 17705102

[27] Calais, J.; Lussato, D.; Merlet, P. Reply to "18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors?". *J. Thorac. Oncol.*, 2015, 10(6), e49-e50.

[28] Bauman, G.; Belohcine, T.; Kovacs, M.; Ward, A.; Bebeshiti, M.; Rachinsky, I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. *Prostate Cancer Prostatis Dis.*, 2012, 15(1), 45-55. http://dx.doi.org/10.1038/pcan.2011.35 PMID: 21844899

[29] Lockman, P.R.; Allen, D.D. The transport of choline. *Drug Dev. Ind. Pharm.*, 2002, 28(7), 749-771. http://dx.doi.org/10.1081/DDI-120020562 PMID: 12256062

[30] Huang, Z.; Rui, J.; Li, X.; Meng, X.; Liu, Q. Use of ¹¹C-Choline positron emission tomography/computed tomography to investigate the mechanism of choline metabolism in lung cancer. *Mol. Med. Rep.*, 2015, 11(5), 3285-3290. http://dx.doi.org/10.3892/mmr.2015.3200 PMID: 25591716

[31] Tian, M.; Zhang, H.; Oriuchi, N.; Higuchi, T.; Endo, K. Comparison of ¹¹C-choline PET and FDG PET for the differential diagnosis of malignant tumors. *Eur. J. Nucl. Med. Mol. Imaging*, 2004, 31(8), 1064-1072. http://dx.doi.org/10.1007/s00259-004-1496-y PMID: 15014903

[32] Konishi, J.; Yamazaki, K.; Tsukamoto, E.; Tamaki, N.; Onodera, Y.; Otake, T.; Morikawa, T.; Kinoshita, I.; Dosaka-Akita, H.; Nishimura, M. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. *Respiration*, 2003, 70(5), 500-506. http://dx.doi.org/10.1159/000074207 PMID: 14665776

[33] Hara, T.; Kosaka, N.; Suzuki, T.; Kudo, K.; Niino, H. Uptake rates of ¹¹C-Choline PET/CT with suspected bronchopulmonary carcinoid. *Clin. Nucl. Med.*, 2015, 40(3), 190-207. http://dx.doi.org/10.1097/RLU.0000000000001017 PMID: 26447388

[34] Zhang, T.; Das, S.K.; Fels, D.R.; Hansen, K.S.; Wong, T.Z.; Dewhirst, M.W.; Vladovic, G. PET with 62Cu-ATSM and 64Cu-ATSM in non-small cell lung cancer. *Lung Cancer*, 2016, 91(6), 56-66. http://dx.doi.org/10.1016/j.lungcan.2015.11.020 PMID: 26719395

[35] Lopci, E.; Grassi, I.; Rubello, D.; Colletti, P.M.; Cambioli, S.; Gamboni, A.; Salvi, F.; Cicoria, G.; Lodi, F.; Dazzi, C.; Mattioli, S.; Fanti, S. Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. *Clin. Nucl. Med.*, 2016, 41(2), e87-e92. http://dx.doi.org/10.1097/RLU.0000000000001017 PMID: 26447388

[36] Zhang, T.; Das, S.K.; Fels, D.R.; Hansen, K.S.; Wang, T.Z.; Dewhirst, M.W.; Vladovic, G. PET with 62Cu-ATSM and 64Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. *AJR Am. J. Roentgenol.*, 2013, 201(5)W698-706. http://dx.doi.org/10.2214/AJR.12.9698 PMID: 24147499

[37] Pietr, M.; Machula, H.-J.; Picchio, M.; Reischl, G.; Ziegler, S.; Kumar, P.; Westerter, H.-J.; Beck, R.; McEwan, A.J.B.; Wiebe, L.J.; Schwaiger, M. Hypoxia-specific tumor imaging with ¹⁸F-fluorodeoxyglucose and [¹⁸F]fluorooxyuridine in lung cancers during radiation therapy. *Acta Oncol.*, 2017, 56(9), 1181-1188. http://dx.doi.org/10.1080/0284186X.2017.1329594 PMID: 28537761
[81] Liu, H.; Rajasekaran, A.K.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; Rahmati, R.; Bader, N.H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. *Cancer Res.*, 1998, 58(18), 4055-4060. PMID: 9751609

[82] Maurer, T.; Eiber, M.; Schwaiger, M.; Gschwend, J.E. Current use of PSMA-PET in prostate cancer management. *Nat. Rev. Urol.*, 2016, 13(4), 226-235. http://dx.doi.org/10.1038/nrurol.2016.26 PMID: 26902337

[83] Pillai, M.R.A.; Nanabala, R.; Joy, A.; Sasikumar, A.; Russ Knapp, F.F. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. *Nucl. Med. Biol.*, 2016, 43(11), 692-720. http://dx.doi.org/10.1016/j.nucmedbio.2016.08.006 PMID: 27589333

[84] Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, C.M. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. *Eur. J. Nucl. Med. Mol. Imaging*, 2013, 40(4), 486-495. http://dx.doi.org/10.1007/s00259-012-2298-2 PMID: 23179945

[85] Afshar-Oromieh, A.; Haberkorn, U.; Eder, M.; Eisenhut, M.; Zechmann, C.M. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. *Eur. J. Nucl. Med. Mol. Imaging*, 2012, 39(6), 1085-1086. http://dx.doi.org/10.1007/s00259-012-2069-0 PMID: 22310854

[86] Afshar-Oromieh, A.; Hetzheim, H.; Kübler, W.; Kratochwil, C.; Giesel, F.L.; Hope, T.A.; Eder, M.; Eisenhut, M.; Kopka, K.; Haberkorn, U. Radiation dosimetry of [68Ga]PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. *Eur. J. Nucl. Med. Mol. Imaging*, 2016, 43(9), 1611-1620. http://dx.doi.org/10.1007/s00259-016-3419-0 PMID: 27260521

[87] Kabasakal, L.; Demirci, E.; Ocak, M.; Akyl, R.; Nematayzar, J.; Aygun, A.; Halac, M.; Talat, Z.; Araman, A. Evaluation of PSMA PET/CT imaging using a [68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. *Nucl. Med. Commun.*, 2015, 36(6), 582-587. http://dx.doi.org/10.1097/NNM.0000000000000290 PMID: 25738559

[88] Schmidt, L.H.; Heatkötter, B.; Schulze, A.B.; Schliemann, C.; Steinestel, K.; Trautmann, M.; Marra, A.; Hillelan, L.; Mohr, M.; Evers, G.; Wardelmann, E.; Rabbar, K.; Görlach, D.; Lenz, G.; Berdel, W.E.; Hartmann, W.; Wiewrodt, R.; Huss, S. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. *PLoS One*, 2017, 12(10) e0186280 http://dx.doi.org/10.1371/journal.pone.0186280 PMID: 29077706

[89] Pyka, T.; Weirich, G.; Einspieler, I.; Maurer, T.; Theisen, J.; Hatzichristodoulou, G.; Schwamborn, K.; Schwaiger, M.; Eiber, M. [68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. *J. Nucl. Med.*, 2016, 57(3), 367-371. http://dx.doi.org/10.2967/jnumed.115.164442 PMID: 26585062

[90] Shetty, D.; Loh, H.; Bui, C.; Mansberg, R.; Stevanovic, A. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. *Clin. Nucl. Med.*, 2016, 41(5), 414-416. http://dx.doi.org/10.1097/RLU.0000000000001139 PMID: 26828144

[91] Jochumsen, M.R.; Gormsen, L.C.; Nielsen, G.L. [68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake. *Clin. Nucl. Med.*, 2018, 43(2), 117-119. http://dx.doi.org/10.1097/RLU.0000000000001935 PMID: 29261620

[92] Virgolini, I.; Decristoforo, C.; Haug, A.; Fanti, S.; Uprimny, C. Current status of theranostics in prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging*, 2018, 45(3), 471-495. http://dx.doi.org/10.1007/s00259-017-3882-2 PMID: 29282518

[93] Loktev, A.; Lindner, T.; Altmann, A.; Jäger, D.; Giesel, F.; Kratochwil, C.; Barthe, P.; Roumestand, C.; Haberkorn, U. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. *J. Nucl. Med.*, 2018, 59(9), 1423-1429. http://dx.doi.org/10.2967/jnumed.118.210435 PMID: 29626120

[94] Conti, M.; Eriksson, L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. *EJNMMI Phys.*, 2016, 5(1), 8. http://dx.doi.org/10.1186/s40658-016-0144-5 PMID: 27271304